Drug intelligence / Profile preview

ORP-103

Development stage: Preclinical
Lead developer: OrphoMed
Modality: Small Molecules

Overview

ORP-103 is a preclinical small-molecule drug candidate initially developed by OrphoMed for the treatment of gastrointestinal motility disorders within the broader category of digestive system disorders. Publicly available pipeline summaries list the program as focused on functional gastrointestinal indications, but no detailed target, molecular class, or pharmacologic mechanism has been disclosed, and no clinical trial entries or regulatory filings are yet associated with this asset.

Beyond the preview

Go deeper on ORP-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORP-103.

Explore the full profile